News

Oblique Therapeutics has yet again received grants from Vinnova.

This year we received funding for 3 different development projects:

  • A new class of selective antagonistic TRPV1 for pain therapyA project we continue to get funded for.
    In collaboration with KI.
  • Engineering of nano-sized membrane vesicles for intracellular delivery of therapeutic antibodiesDesigning a new technology to get antibodies inside the cell
    A project in collaboration with KTH, KI and SLU
  • Improved cancer diagnostic and drug developmentA project in collaboration with RISE among others